You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antineoplastic Agents;Molecular Mechanisms of Pharmacological Action

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +14 more
  • Glendale, California
  • +12 more
Feb 2, 2023

Molecular Mechanisms of Pharmacological Action, Depression, Depressive Disorder Trial in Oxford (Prucalopride, Placebo)

Completed
  • Molecular Mechanisms of Pharmacological Action
  • +6 more
  • Oxford, United Kingdom
    University of Oxford
Nov 14, 2022

Hepatocellular Carcinoma, Liver Tumors, Digestive System Tumors Trial in Chengdu (TACE combined with sorafenib and PD-1 mAb)

Recruiting
  • Hepatocellular Carcinoma
  • +7 more
  • TACE combined with sorafenib and PD-1 mAb
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital and Research Institute
Sep 14, 2020

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

Recruiting
  • Non-Small Cell Lung Cancer
  • +13 more
  • furmonertinib 240 mg
  • +2 more
  • Yuma, Arizona
  • +37 more
Dec 14, 2022

Ovarian Tumors, Fallopian Tube Tumors, Endocrine Gland Tumors Trial in Nanjing (Niraparib, Bevacizumab)

Unknown status
  • Ovarian Neoplasms
  • +23 more
  • Nanjing, Jiangsu, China
    JiangSu Cancer Hospital
Nov 8, 2020

Prader-Willi Syndrome, Aggression, Self-Injurious Behavior Trial in Brooklyn (Guanfacine Extended Release, Placebo)

Recruiting
  • Prader-Willi Syndrome
  • +20 more
  • Guanfacine Extended Release
  • Placebo
  • Brooklyn, New York
    Maimonides Medical Center
Dec 20, 2022

Breast Cancer, Tumor, Breast, Breast Diseases Trial in Poland (Sacubitril-valsartan)

Not yet recruiting
  • Breast Cancer
  • +12 more
  • Opole, Opolskie, Poland
  • +3 more
Jul 15, 2022

Stroke, Cerebrovascular Disorders, Ischemic Stroke Trial in Beijing, Tianjin (Propranolol, Ceftriaxone)

Not yet recruiting
  • Stroke
  • +11 more
  • Beijing, China
  • +1 more
May 11, 2022

Tobacco Dependence, Smoking Cessation, Tobacco Smoking Trial in Toronto (Varenicline, Active tDCS, Sham tDCS)

Completed
  • Tobacco Dependence
  • +6 more
  • Toronto, Ontario, Canada
    Centre for Addiction and Mental Health
Mar 14, 2022

Schizophrenia, Psychotic Disorders, Mood Disorders Trial in United States (LY03010 156 mg treatment group, deltoid, LY03010 156

Recruiting
  • Schizophrenia
  • +11 more
  • LY03010 156 mg treatment group, deltoid
  • +3 more
  • Little Rock, Arkansas
  • +8 more
Apr 11, 2022

Schizophrenia, Psychotic Disorders, Mood Disorders Trial in United States (LY03010; paliperidone palmitate, INVEGA SUSTENNA)

Active, not recruiting
  • Schizophrenia
  • +11 more
  • LY03010; paliperidone palmitate
  • INVEGA SUSTENNA
  • Garden Grove, California
  • +8 more
Nov 19, 2021

Delirium, Cognitive Dysfunction, Cognition Disorder Trial in Toronto (Dexmedetomidine Hydrochloride Group)

Recruiting
  • Delirium
  • +16 more
  • Dexmedetomidine Hydrochloride Group
  • Toronto, Ontario, Canada
    Sunnybrook Health Sciences Centre
Mar 14, 2022

Solid Tumor, Adult Trial in Providence, Nashville (DF6215)

Not yet recruiting
  • Solid Tumor, Adult
  • Providence, Rhode Island
  • +1 more
Oct 25, 2023

Testicular Tumors, Tumors, Germ Cell and Embryonal, Tumors Trial in Bratislava (Avelumab)

Completed
  • Testicular Neoplasms
  • +6 more
  • Bratislava, Slovakia
    National Cancer Institute
Mar 3, 2019

Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory DLBCL Trial in Canada (DPX-Survivac, Pembrolizumab,

Active, not recruiting
  • Adult Diffuse Large Cell Lymphoma
  • +2 more
  • DPX-Survivac
  • +2 more
  • Calgary, Alberta, Canada
  • +5 more
Nov 9, 2022

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)

Recruiting
  • Leukemia
  • +19 more
  • CYNK-001
  • Denver, Colorado
  • +9 more
Sep 9, 2022

Breast Cancer After Ovarian Cancer During and/or After Therapy:

Recruiting
  • BRCA-Associated Breast Carcinoma
  • Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Mar 9, 2023

Molecular Mechanisms of Pharmacological Action, Depression, Depressive Disorder Trial in Oxford (Citalopram, Placebo oral

Unknown status
  • Molecular Mechanisms of Pharmacological Action
  • +5 more
  • Oxford, United Kingdom
    University of Oxford
Nov 18, 2019

Breast Tumors, Breast Cancer, HER2-positive Early Breast Cancer Trial in Worldwide (Trastuzumab Deruxtecan, Paclitaxel,

Recruiting
  • Breast Neoplasms
  • +2 more
  • Trastuzumab Deruxtecan
  • +5 more
  • Springdale, Arkansas
  • +203 more
Jan 13, 2023

CIPN and it's Impact on Quality of Life in Patients Receiving

Not yet recruiting
  • Chemotherapy-induced Peripheral Neuropathy
    • (no location specified)
    Apr 24, 2023

    2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease Trial in United States (Famotidine,

    Terminated
    • 2019 Novel Coronavirus Disease
    • +11 more
    • Newport Beach, California
    • +14 more
    Jul 20, 2022

    Endometrial Cancer, Serous Adenocarcinoma, Uterine Tumor Trial (Niraparib oral capsule)

    Not yet recruiting
    • Endometrial Cancer
    • +2 more
    • Niraparib oral capsule
    • (no location specified)
    Oct 31, 2022

    Cardiomyopathy, Familial Trial in Montpellier (Electrocardiogram, physical examination, echocardiography)

    Completed
    • Cardiomyopathy, Familial
    • Electrocardiogram
    • +3 more
    • Montpellier, Occitanie, France
      CHU Arnaud de Villeneuve
    Dec 13, 2022

    Acute Myeloid Leukemia Trial in Valencia (AFM28)

    Recruiting
    • Acute Myeloid Leukemia
    • Valencia, Spain
      Hospital Universitari i Politècnic La Fe
    Apr 5, 2023

    Molecular Modulation of the Growth Plate

    Enrolling by invitation
    • Growth Plate Injury
      • Rochester, Minnesota
        Mayo Clinic'
      Mar 16, 2022